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Cumulative doses of radioiodine in 
the treatment of differentiated thyroid 
carcinoma: knowing when to stop
Doses cumulativas de iodo radioativo no tratamento do 
carcinoma diferenciado de tireoide: sabendo a hora de parar
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ABSTRACT
Objective: Evaluate the efficacy of cumulative doses (CDs) of 131I-iodide therapy (RIT) in diffe-
rentiated thyroid cancer (DTC). Subjects and methods: The probability of progressive disease 
according to CDs was evaluated in patients ≤ 45 years old and > 45 years old and correlated to 
tumor-node-metastasis (TNM), thyroglobulin values, histological types and variants, age, and 
zduration of the disease. Results: At the end of a follow-up period of 69 ± 56 months, 85 out 
of 150 DTC patients submitted to fixed doses RIT had no evidence of disease, 47 had stable 
disease and 18 had progressive disease. Higher CDs were used in the more aggressive variants 
(p < 0.0001), higher TNM stages (p < 0.0001), and follicular carcinomas (p = 0.0034). Probability 
of disease progression was higher with CDs ≥ 600 mCi in patients > 45 years old and with CDs 
≥ 800 mCi in patients ≤ 45 years. Conclusion: Although some patients may still respond to high 
CDs, the impact of further RIT should be carefully evaluated and other treatment strategies may 
be warranted. Arq Bras Endocrinol Metab. 2010;54(9):807-12
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RESUMO
Objetivo: Avaliar a eficácia de doses cumulativas (DCs) da terapia com iodeto-131I (RIT) no cân-
cer diferenciado de tiroide (CDT). Sujeitos e métodos: A probabilidade de doença em progres-
são conforme a DC foi calculada em pacientes com idade ≤ 45 e > 45 anos e correlacionada 
com o TNM, valores de tiroglobulina sérica, tipos histológicos e variantes, idade e tempo de 
doença. Resultados: Ao final de um seguimento de 69 ± 56 meses, 85 dos 150 pacientes CDT 
submetidos a doses fixas de RIT não tinham evidência de doença, 47 tinham doença estável e 
18, doença progressiva. DCs mais elevadas foram usadas nas variantes agressivas (p < 0,0001), 
maior estágio TNM (p < 0,0001) e nos carcinomas foliculares (p = 0,0034). A probabilidade de 
doença em progressão foi maior com DCs ≥ 600 mCi em pacientes > 45 anos e com DCs ≥ 800 
mCi em pacientes ≤ 45 anos. Conclusão: Apesar de alguns pacientes ainda responderem a altas 
DCs, o impacto de RITs deve ser cuidadosamente avaliado e outras estratégias terapêuticas 
devem ser consideradas. Arq Bras Endocrinol Metab. 2010;54(9):807-12
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INTRODUCTION
Differentiated thyroid cancer incidence has been ris-ing all over the world and recent data demonstrate 
that rates have also increased for large and aggressive 
tumors diagnosed with distant metastasis (SEER stage) 
(1-3). Standard treatment for DTC patients includes 
total or near-total thyroidectomy followed by adjuvant 
radioiodine therapy (RIT) to destroy remnant, benign 
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or malignant thyroid tissue (4-6). Two methods are 
widely available: the so-called fixed empirical method 
currently used by most medical services, and the do-
simetric method. There is still no evidence of a clear 
advantage of one method over the other for the calcula-
tion of the administered dose (7).
The majority of patients with DTC have a good 
prognosis and high cure rates (8.9). However, the dise-
ase persists or recurs with a considerable impact on qua-
lity of life in up to 60% of the patients (8,9). Depending 
on the course of the disease additional treatments using 
radioiodine may become necessary. As long as metasta-
ses and recurrences are radioiodine-avid, it is the most 
effective treatment option and high response rates are 
achievable (10). Unfortunately, approximately 15% of 
these patients do not respond to RIT (8-11). Improved 
survival is associated with responsiveness to RIT (12).
There is no pre-established timing in the literature 
of when to stop RIT. Limits to 1,000 mCi have been 
suggested; however, they are empirical and do not con-
sider all variables such as stage, tumor histology, age, 
tumor marker levels, clinical course, side effects and 
quality of life during RIT (5-7,12,13). Thus, many pa-
tients are submitted to cumulative doses of up to 2 Ci, 
however, the actual benefit of this is questionable. 
The aim of this study was to evaluate the efficacy 
of RIT in DTC regarding cumulative doses and its re-
lationship with the clinical course, primary tumor his-
tology, stage, age and serum thyroglobulin (Tg) levels. 
MATERIAL AND METHODS
Patients
This retrospective case-control study was approved 
by the Research Ethics Committee of the Faculty of 
Medical Sciences – Universidade Estadual de Campi-
nas (FCM-Unicamp). We analyzed the records of 232 
DTC patients who were submitted to RIT with 131I-
-iodide. After excluding patients with incomplete data, 
150 patients were selected for the study (125 women; 
mean age of 44.3 ± 14.6 years). 
All patients were managed according to a standard pro-
tocol which included total thyroidectomy. Patients with 
preoperatively or intraoperatively palpable neck node me-
tastases underwent regional neck dissection. At the time 
of the initial treatment, surgical specimen was analyzed 
and classified according to the WHO classification, and 
patients were classified according to the sixth edition of 
the The American Joint Committee on Cancer (AJCC)/
International Union Against Cancer (UICC) TNM (14).
Radioiodine therapy (RIT)
RITs were performed with fixed doses, as follows: 
3,700 MBq (100 mCi) for thyroid remnants, 5,550 
MBq (150 mCi) for lymph node metastases, 7,400 
MBq (200 mCi) for pulmonary metastases, 11,100 
MBq (300 mCi) for bone metastases. 
In patients who required second or third RIT the 
decision on the new dose was based on the location of 
the metastases, on the dose previously administered, on 
persistently elevated Tg levels (with or without positive 
WBI), and to some extent on tumor volume, normally 
adding 925 MBq to 1,850 MBq (25-50 mCi) to the 
new dose. For example, a patient with thyroid remnants 
after total thyroidectomy without lymph node metasta-
ses would initially receive 3,700 MBq (100 mCi) of 131I-
-iodide. If this patient presented with persistent thyroid 
remnants on follow-up scans, without lymph node me-
tastases, another RIT would be performed with 4,625 
– 5,550 MBq (125-150 mCi) of 131I-iodide. However, 
if this same patient required a new treatment due to the 
appearance of bone metastasis in follow-up, RIT would 
be performed with 11,100 MBq (300 mCi). 
Lymph node metastases were diagnosed after total 
thyroidectomy with cervical neck dissection or during 
follow-up. 
Follow-up
Patient follow-up ranged from 19 to 383 months 
(mean 69 ± 56 months, median 49.15 months). Accor-
ding to a routine protocol, follow-up included periodic 
total body scans, serum TSH and Tg measurements, as 
well as other eventual procedures to detect distant me-
tastasis, including cervical ultrasound, chest CT, whole 
body iodide scan (WBI), whole body 99mTc- sestamibi 
scan (after the year 1992), 18F-FDG PET/CT (after 
the year 2007), and biopsy. Stimulated Tg levels were 
obtained when whole body scans (WBS) were perfor-
med. A first serum Tg result (Tg1) was obtained before 
patients underwent the first RIT, the second Tg (Tg2) 
was obtained after a second RIT (when indicated), and 
the same criterion was considered for the third (Tg3), 
fourth (Tg4) and ensuing Tg measurements. Using 
these parameters disease status was classified as: no evi-
dence of disease (NED), stable disease (SD) and pro-
gressive disease (PD). This classification was established 
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when the maximum tolerated dose for each patient was 
determined. There was no variation of this classification 
during the study. 
NED was established as: undetectable Tg levels 
(with or without levothyroxine suppression), two 
consecutive WBI scans without local-regional uptake 
or distant metastases; other imaging studies (cervical 
ultrasounds, chest CTs, whole body 99mTc-sestamibi 
scans, 18F-FDG PET/CT scans) without evidence of 
disease; suppressed serum Tg level < 2.0 ng/mL and 
stimulated serum Tg level < 10.0 ng/mL.
SD was established as: unaltered Tg levels, persis-
tent cervical uptake and/or metastases in annual WBI, 
suppressed serum Tg level > 2.0 ng/mL or serum Tg 
level > 10.0 ng/mL but without progressive elevation 
and no new metastatic foci. 
PD was established as: increasing serum Tg levels 
despite RIT and/or new metastatic foci detected by 
imaging studies. Patients with PD were treated surgi-
cally whenever possible whether the metastases were 
loco-regional or distant. This approach was performed 
in order to improve the efficacy of RIT (15).
Table 1 summarizes median Tg levels and RIT do-
ses administered to patients after the corresponding 
evaluation.
-Wallis test followed by the Tukey’s test was used to lo-
cate these differences. Spearman’s linear coefficient was 
applied to verify the relationship among continuous 
variables. A multiple logistic regression analysis adjus-
ting age and follow-up time was used to identify factors 
associated with the evidence of disease. In order to cal-
culate the estimated probability of disease status (NED, 
SD or PD), we created a model that took into account 
the age (above or below 45 years) and the cumulative 
dose. The significance level applied was 5%. 
RESULTS
Papillary carcinomas (PC) were found in 125 cases and 
follicular carcinomas (FC) in the remaining 25 cases. An 
experienced pathologist (PSM) classified the tumors as 
“classic DTC” (116 cases) or as having an “aggressive his-
tology”; the latter included 34 patients (22.7%) presenting 
Hürthle cell, invasive FC, tall cell variant, diffuse sclerosis 
variant or columnar cell variant of PC. Eighty-five cases 
(56.7%) were considered a TNM stage I, 28 were stage 
II (18.7%); 14 stage III (9.3%), and 23 stage IV (15.3%). 
Table 2 summarizes the patient data. 
Eighty-five out of the 150 patients (56.7%) were 
classified as NED; 47 patients had SD (31.3%), and the 
remaining 18 patients had PD (12.0%).
Table 1. Serum median Tg levels 1 to 4 and median 131I-iodide therapy 
(RIT) corresponding administered doses 1 to 4
Patient data Number of patients Median
Tg1 (ng/mL)
Dose 1
150 3.35
101.50
Tg2 (ng/mL)
Dose 2
64 4.10
200.00
Tg3 (ng/mL)
Dose 3
30 25.50
250.00
Tg4 (ng/mL)
Dose 4
11 36.90
330.00
Tg/ stimulated TSH
Cumulative dose (mCi)
150
150
0.69
150.00
Seven patients with PD had non-avid radioiodine 
metastasis and one patient died after 8 years of DTC 
diagnosis, due to a second primary tumor. This patient 
had received a CD of 300 mCi.
Statistical analysis 
The chi-squared test or the Fisher’s exact test was per-
formed in order to verify associations or compare pro-
portions. The Mann-Whitney test was applied to com-
pare continuous variables between two groups. For 
three or more variables among groups, the Kruskal-
Table 2. Clinical and pathological features at diagnosis of 150 patients 
with differentiated thyroid carcinomas followed-up from 19 to 383 months 
after 131I-iodide therapy (RIT)
Cumulative 
frequency Percentage
Sex
Female 125 83.3
Male 25 16. 7
Histology
Papillary carcinomas 125 83.3
Follicular carcinomas 25 16.7
Variant
Classical 116 77.3
Aggressive 34 22.7
Invasive follicular carcinoma 6 17.7*
Hurtle 10 29.4*
Tall cell 12 35.3*
Diffuse sclerosis 3 8.8*
Columnar cells 3 8.8*
TNM stage
I 85 56.7
II 28 18.7
III 14 9.3
IV 23 15.3
* Percentages relative to the group of 34 cases of aggressive differentiated thyroid carcinomas.
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Tg1 levels ranged from 0 to 6,000 ng/mL; Tg2 le-
vels were obtained in 71 patients and ranged from 0.2 
ng/mL to 6,000 ng/mL; Tg3 levels were obtained in 
31 patients and ranged from 0.2 ng/mL to 3,000 ng/
mL, and Tg4 levels were obtained in 11 patients and 
also ranged from 0.2 ng/mL to 3,000 ng/mL.
Among the 49 patients with Tg1 levels above 10 ng/
mL that evolved with NED, in 7 patients this occurred 
after the first RIT dose while 42 patients required more 
treatment sessions. Thus, RIT was completely effective 
in treating thyroid remnants in 14% of the cases and was 
effective treating the actual disease in 86% of the patients.
After the first RIT, 79 patients were deemed with 
SD or NED. Hence, the RIT was effective and no new 
treatment was necessary for these cases. Tg levels ran-
ged from 0 to 86 ng/mL in this group. The remaining 
71 patients required a second RIT. After the second 
RIT, 40 patients were considered with SD or NED 
and their Tg levels ranged from 0 to 516 ng/mL. The 
remaining 31 patients required a third RIT. After the 
third RIT, 20 patients were classified as presenting SD 
or NED and their Tg levels ranged from 0 to 170 ng/
mL. The remaining 11 patients required a fourth RIT. 
A striking response was seen in a few patients with 
high serum Tg levels. Six out of the 150 patients had Tg1 
levels above 500 ng/mL. All 6 patients presented with 
pulmonary metastases although in 2 of them the WBI 
scans were negative. The only patient with Tg1 above 
6,000 ng/mL had bone and pulmonary metastases. 
Among the 6 patients that had serum Tg1 levels > 500 
ng/mL after a second RIT, two patients responded to 
RIT treatment and 4 patients maintained Tg2 levels abo-
ve 700 ng/mL and pulmonary metastases. Among these 
4 patients with serum Tg2 levels > 700 ng/mL one pa-
tient responded to RIT and the remaining 3 maintained 
serum Tg levels above 500 ng/mL (two with pulmonary 
metastases and one with a mediastinal lymph node). 
Table 3 summarizes the positive associations confir-
med by a multiple logistic regression analysis that sho-
wed the disease status was associated with the TNM sta-
ge and age on the occasion of diagnosis, with the initial 
stimulated serum Tg levels and with the cumulative dose.
Higher cumulative doses were used in the more ag-
gressive histologic variants (p < 0.0001), higher TNM 
stage tumors (p < 0.0001), and follicular carcinomas 
(p = 0.0034), while no association was observed with 
gender (p = 0.1469). Patients with aggressive histolo-
gic variants received almost twice the dose (464 ± 318 
mCi) of the non-aggressive variants (240 ± 192 mCi; 
Table 3. Multiple logistic regression analysis of disease status and 
variables studied 
Variables Disease status p-value OR 95% CI
TNM stage SD vs. NED 0.0063 4.203 1.499; 11.783
PD vs. NED 0.0016 9.126 2.310; 36.053
Age SD vs. NED 0.0331 0.970 0.943; 0.998
PD vs. NED 0.6024 1.013 0.966; 1.062
Cumulative dose SD vs. NED < 0.0001 1.005 1.003; 1.008
PD vs. NED < 0.0001 1.010 1.006; 1.014
Stimulated  
Tg levels
SD vs. NED 0.0007 1.413 1.157; 1.727
PD vs. NED 0.0005 1.430 1.170; 1.747
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Figure 1. Probability of disease status according to the cumulative doses 
of RIT for patients ≤ 45 years of age.   
Figure 2. Probability of disease status according to cumulative doses of 
RIT for patients above 45 years of age. 
p < 0.0001). The highest cumulative dose given in this 
group was 1,100 mCi. 
The statistic model was created in order to estimate 
the probability of disease status (RD, SD or PD) accor-
ding to the cumulative dose in patients above and be-
low 45 years of age and is displayed in figures 1 and 2.
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DISCUSSION
There are many studies discussing clinical, pathological 
and molecular factors related to the prognosis of DTC. 
However, only a few authors have focused on the im-
pact of the cumulative dose of RIT. The relatively long 
follow-up period in the present study (up to 32 years) 
has made it possible to evaluate tumor behavior com-
pared to RIT cumulative doses and their effect on sur-
vival. As expected, patients with higher serum Tg levels 
during the course of the disease had progressive disease 
and therefore required higher and more frequent thera-
peutic 131I-iodide doses. Also, in accordance to others, 
we observed that patients with Hürthle cell, invasive 
FC, tall cell, diffuse sclerosis variant, columnar cells had 
the worst prognosis (16). These variants have high vas-
cularity and therefore have a higher risk of hematoge-
nic spread. They also frequently present metastases at 
diagnosis (16), which explains why these patients had 
PD and therefore significant higher cumulative doses 
of RIT. The association between cumulative dose and 
TNM stage was also expected considering that the hi-
gher stages (III and IV) have a worse prognosis (17,18). 
However, there are conflicting reports in the literature 
regarding the influence of the histological type (PC vs. 
FC) on DTC prognosis (19). Mazzaferri and cols. re-
ported similar progression rates when distant metasta-
ses were excluded at diagnosis, with FC and PC similar 
mortality rates (10% vs. 6%, p = N/S) (20).
Patients with higher staging (III and IV), above 45 
years of age, and aggressive variants have a worse prog-
nosis, greater chances of local recurrence and distant 
metastases, and require higher and more RIT doses. 
Consequently, higher cumulative doses are seen in this 
subgroup of patients as the endpoint is prolonging ove-
rall survival. In order to estimate the probability of the 
possible outcome of these patients, a probability model 
was created. The estimated probability model was de-
signed to evaluate the relationship between cumulative 
dose and disease status and thus determine a specific 
cumulative dose for which the probability of disease 
progression would be high despite the RIT dose. With 
our patient population, based on this model, we may 
suppose that a patient below the age of 45 years has 
approximately 70% chance of complete remission of the 
disease with a cumulative dose of only 100 mCi while 
the same patient, if requiring cumulative doses in the 1 
Ci range may still have a 27% chance of stabilizing the 
disease. 
We observed that there is a high probability of di-
sease progression with cumulative doses of 600 mCi in 
patients above 45 years of age, although a few individu-
als do respond to cumulative doses above 1,000 mCi. 
The disease will only continue to progress in younger 
patients (≤ 45 years) with higher cumulative doses (800 
mCi or higher), despite the fact that some patients may 
still respond to cumulative doses above 1,000 mCi. 
A recent study of 77 DTC patients with distant me-
tastases followed-up for a median of 6.1 years reported 
similar data concluding that age had significantly gre-
ater influence on survival than iodine avidity (21,22).
The evaluation of Tg levels throughout this long 
period of time is challenging and some variability exis-
ted since new techniques with less false negative results 
have emerged throughout the years. Reference values 
were determined according to the period in which they 
were analyzed and in patients in whom these values 
were discrepant with history and imaging studies, new 
analyses were performed. Treatment strategies were 
always based on discussion with a multidisciplinary 
team to minimize possible discrepancies (23). 
Unfortunately, we were not able to evaluate the im-
pact on overall survival vs. cumulative dose since the 
mean follow-up time was below 10 years. A longer 
follow-up time with a larger number of patients is ne-
cessary in order to evaluate the impact of this informa-
tion on patient management. 
In conclusion, although there is no actual cutoff 
point indicating when RIT should not be considered 
for therapy, these data indicate caution in patients abo-
ve 45 years old receiving cumulative doses higher than 
600 mCi, as well as in younger patients who have alrea-
dy received cumulative doses above 800 mCi. Although 
some patients may still respond to cumulative doses 
above these levels, we should carefully evaluate the im-
pact of further RIT on their quality of life considering 
the disease progression rate in between treatments and 
the availability of other measures, including surgical 
excision of metastasis, ethanol ablation, chemo-embo-
lization or the emerging targeted molecular therapies. 
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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